Comparison of and Frequency of Mortality, Left Ventricular Assist Device Implantation, Ventricular Arrhythmias, and Heart Transplantation in Patients With Familial Versus Nonfamilial Idiopathic Dilated Cardiomyopathy.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 09 2022
Historique:
received: 28 02 2022
revised: 23 05 2022
accepted: 06 06 2022
pubmed: 1 8 2022
medline: 31 8 2022
entrez: 31 7 2022
Statut: ppublish

Résumé

We postulated that familial idiopathic dilated cardiomyopathy (F-IDC) is associated with a worse prognosis than nonfamilial IDC (nonF-IDC). Patients with F-IDC had either a strong family history and/or proved genetic mutations. We studied long-term prognosis (mean follow-up: 6.1 ± 4.1 years) of 162 patients with IDC (age: 55.5 ± 17.9 years, men: 57.8%, 50% F-IDC) with an implantable cardioverter-defibrillator or cardiac resynchronization therapy. The primary end point was a composite of death, left ventricular (LV) assist device implant, or heart transplantation. The secondary end point was a ventricular arrhythmia event. There was no significant difference in the prevalence of diabetes, hypertension, New York Heart Association class, medical therapy, and years of follow-up between the F-IDC and nonF-IDC groups. Patients with F-IDC were younger than patients with nonF-IDC (49.1 ± 17.0 years vs 61.6 ± 16.5 years, p <0.001). Mean LV ejection fraction was significantly lower in F-IDC group than in the nonF-IDC group (26 ± 12% vs 31 ± 12%, p = 0.022). The primary end point was achieved in 54 patients in F-IDC group (66.7%) versus 19 in the nonF-IDC group (23.5%) (p <0.001). The Kaplan-Meier survival estimates for the composite end point and for ventricular arrhythmia were significantly lower in the F-IDC versus nonF-IDC (log-rank p ≤0.001 and 0.04, respectively). F-IDC was the only multivariable predictor of the primary composite end point (hazard ratio 3.419 [95% confidence interval 1.845 to 6.334], p <0.001). The likelihood of LV remodeling manifested by LV ejection fraction improvement (≥10%) was significantly lower in F-IDC than nonF-IDC (27.1% vs 44.8%, p = 0.042). In conclusion, F-IDC is a predictor of mortality, need for LV assist device, or heart transplantation. F-IDC is associated with significantly lower event-free survival for primary end point and ventricular arrhythmia than nonF-IDC. F-IDC has significantly lower likelihood of LV reverse remodeling than nonF-IDC.

Identifiants

pubmed: 35909017
pii: S0002-9149(22)00652-X
doi: 10.1016/j.amjcard.2022.06.018
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

83-89

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosures The authors have no conflicts of interest to declare.

Auteurs

Roopa A Rao (RA)

Cardiovascular Institute, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana.

Elie Kozaily (E)

Cardiovascular Institute, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana.

Omar Jawaid (O)

Cardiovascular Institute, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana.

Mohammad Sabra (M)

Cardiovascular Institute, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana.

Edward A El-Am (EA)

Cardiovascular Institute, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana.

Rody G Bou Chaaya (RGB)

Cardiovascular Institute, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana.

Leanne Woiewodski (L)

Cardiovascular Institute, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana.

Hussein Elsemesmani (H)

Cardiovascular Institute, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana.

Juhi Ramchandani (J)

Cardiovascular Institute, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana.

Chirag Shah (C)

Cardiovascular Institute, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana.

Maya Guglin (M)

Cardiovascular Institute, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana.

Mithilesh K Das (MK)

Cardiovascular Institute, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana. Electronic address: midas@iu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH